Franklin Resources’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-14,166
Closed -$1.44M 2825
2023
Q2
$1.44M Buy
14,166
+11,259
+387% +$1.07M ﹤0.01% 1521
2023
Q1
$264K Buy
+2,907
New +$171K ﹤0.01% 1906
2022
Q4
Sell
-294,889
Closed -$7.41M 2402
2022
Q3
$7.41M Sell
294,889
-338,767
-53% -$9.39M ﹤0.01% 1006
2022
Q2
$19.3M Sell
633,656
-218,502
-26% -$6.52M 0.01% 807
2022
Q1
$27.9M Sell
852,158
-105
-0% -$3.12K 0.01% 763
2021
Q4
$22.5M Sell
852,263
-172,035
-17% -$13.3M 0.01% 860
2021
Q3
$103M Sell
1,024,298
-363,662
-26% -$42.6M 0.04% 467
2021
Q2
$196M Sell
1,387,960
-71,829
-5% -$8.11M 0.08% 294
2021
Q1
$146M Sell
1,459,789
-2,138
-0.1% -$249K 0.06% 342
2020
Q4
$181M Buy
1,461,927
+68,273
+5% +$8.97M 0.08% 284
2020
Q3
$136M Buy
1,393,654
+60,573
+5% +$7.57M 0.07% 317
2020
Q2
$213M Buy
1,333,081
+131,210
+11% +$19.9M 0.11% 224
2020
Q1
$174M Sell
1,201,871
-41,260
-3% -$7.97M 0.12% 206
2019
Q4
$254M Sell
1,243,131
-11,896
-0.9% -$2.17M 0.13% 192
2019
Q3
$101M Buy
1,255,027
+96,297
+8% +$8.17M 0.05% 370
2019
Q2
$109M Buy
1,158,730
+179,994
+18% +$15.5M 0.06% 354
2019
Q1
$83.7M Buy
978,736
+17,437
+2% +$1.45M 0.04% 411
2018
Q4
$53.9M Buy
961,299
+102,286
+12% +$6.24M 0.03% 473
2018
Q3
$70.2M Buy
859,013
+593,552
+224% +$41.8M 0.04% 458
2018
Q2
$9.28M Buy
265,461
+27
+0% +$822 ﹤0.01% 935
2018
Q1
$5.44M Hold
265,434
﹤0.01% 1032
2017
Q4
$7.52M Buy
265,434
+15,392
+6% +$429K ﹤0.01% 998
2017
Q3
$7.78M Buy
+250,042
New +$7.52M ﹤0.01% 1004

Other funds holding RETA

Franklin Resources's RETA Position: Q3 2023 in Review

Franklin Resources sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 14,166 shares — an estimated $1.44M sold.

Franklin Resources first reported a position in RETA in Q3 2017 and held it in 23 quarters. The position peaked at $254M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Franklin Resources reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Franklin Resources sold 14,166 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.44M.
  • Franklin Resources first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 23 quarters.
  • Franklin Resources's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $254M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Franklin Resources's 13F filing for Q3 2023, filed 13 Nov 2023.